UBS AM
RARE icon

UBS AM’s Ultragenyx Pharmaceutical RARE Stock Holding History

UBS AM’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.58M Sell
167,226
-55,822
-25% -$1.39M ﹤0.01% 1551
2026
Q1 		$4.67M Buy
223,048
+18,941
+9% +$427K ﹤0.01% 1585
2025
Q4 		$4.69M Sell
204,107
-2,935
-1% -$96.5K ﹤0.01% 1495
2025
Q3 		$6.23M Sell
207,042
-93,920
-31% -$2.82M ﹤0.01% 1265
2025
Q2 		$10.9M Buy
300,962
+68,602
+30% +$2.47M ﹤0.01% 1313
2025
Q1 		$8.41M Buy
232,360
+29,984
+15% +$1.25M ﹤0.01% 1309
2024
Q4 		$8.51M Buy
202,376
+24,620
+14% +$1.22M ﹤0.01% 1326
2024
Q3 		$9.87M Buy
177,756
+947
+0.5% +$48.2K ﹤0.01% 1228
2024
Q2 		$7.27M Buy
176,809
+46,549
+36% +$1.99M ﹤0.01% 1284
2024
Q1 		$6.08M Buy
130,260
+12,054
+10% +$569K ﹤0.01% 1172
2023
Q4 		$5.65M Buy
118,206
+3,685
+3% +$143K ﹤0.01% 1194
2023
Q3 		$4.08M Buy
114,521
+8,554
+8% +$339K ﹤0.01% 1301
2023
Q2 		$4.25M Hold
105,967
– – ﹤0.01% 1312
2023
Q1 		$4.25M Sell
105,967
-15,952
-13% -$685K ﹤0.01% 1312
2022
Q4 		$5.65M Buy
121,919
+23,282
+24% +$916K ﹤0.01% 1128
2022
Q3 		$4.08M Sell
98,637
-16,039
-14% -$824K ﹤0.01% 1266
2022
Q2 		$6.84M Sell
114,676
-507
-0.4% -$31.2K ﹤0.01% 1098
2022
Q1 		$8.36M Buy
115,183
+11,669
+11% +$812K ﹤0.01% 1139
2021
Q4 		$8.7M Buy
103,514
+10,801
+12% +$879K ﹤0.01% 1178
2021
Q3 		$8.36M Sell
92,713
-2,558
-3% -$231K ﹤0.01% 1155
2021
Q2 		$9.08M Buy
95,271
+22,754
+31% +$2.37M ﹤0.01% 1152
2021
Q1 		$8.26M Buy
72,517
+4,116
+6% +$560K ﹤0.01% 1144
2020
Q4 		$9.47M Buy
68,401
+3,066
+5% +$364K ﹤0.01% 1075
2020
Q3 		$5.37M Buy
65,335
+5,237
+9% +$434K ﹤0.01% 1124
2020
Q2 		$4.7M Sell
60,098
-310
-0.5% -$20.5K ﹤0.01% 1138
2020
Q1 		$2.68M Buy
60,408
+988
+2% +$51.3K ﹤0.01% 1294
2019
Q4 		$2.54M Buy
59,420
+1,336
+2% +$55.1K ﹤0.01% 1489
2019
Q3 		$2.48M Buy
58,084
+9,744
+20% +$529K ﹤0.01% 1511
2019
Q2 		$3.07M Buy
48,340
+4,577
+10% +$291K ﹤0.01% 1398
2019
Q1 		$3.04M Buy
43,763
+8,314
+23% +$475K ﹤0.01% 1340
2018
Q4 		$1.54M Buy
35,449
+1,676
+5% +$91.6K ﹤0.01% 1543
2018
Q3 		$2.58M Buy
33,773
+603
+2% +$49K ﹤0.01% 1400
2018
Q2 		$2.55M Sell
33,170
-260
-0.8% -$16.8K ﹤0.01% 1400
2018
Q1 		$1.7M Buy
33,430
+6,768
+25% +$341K ﹤0.01% 1538
2017
Q4 		$1.24M Buy
26,662
+1,636
+7% +$80.2K ﹤0.01% 1652
2017
Q3 		$1.33M Buy
25,026
+1,390
+6% +$82.4K ﹤0.01% 1580
2017
Q2 		$1.47M Buy
23,636
+3,795
+19% +$229K ﹤0.01% 1487
2017
Q1 		$1.34M Buy
19,841
+7,128
+56% +$543K ﹤0.01% 1513
2016
Q4 		$894K Sell
12,713
-8,606
-40% -$611K ﹤0.01% 1600
2016
Q3 		$1.51M Buy
21,319
+1,660
+8% +$106K ﹤0.01% 1488
2016
Q2 		$962K Buy
19,659
+7,492
+62% +$485K ﹤0.01% 1674
2016
Q1 		$770K Sell
12,167
-47,979
-80% -$3.14M ﹤0.01% 1745
2015
Q4 		$6.75M Sell
60,146
-761
-1% -$76.1K 0.01% 971
2015
Q3 		$5.87M Buy
60,907
+51,307
+534% +$5.87M 0.01% 1008
2015
Q2 		$983K Buy
9,600
+1,500
+19% +$116K ﹤0.01% 1687
2015
Q1 		$503K Buy
8,100
+3,500
+76% +$194K ﹤0.01% 1979
2014
Q4 		$202K Buy
+4,600
New +$211K ﹤0.01% 2465

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

UBS AM's RARE Position: Q2 2026 in Review

UBS AM reduced its Ultragenyx Pharmaceutical (RARE) stake by 25% in Q2 2026, selling an estimated $1.39M and leaving 167,226 shares worth $5.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1551.

UBS AM first reported a position in RARE in Q4 2014 and has held it in 47 quarters since. The position peaked at $10.9M in Q2 2025. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • UBS AM held 167,226 shares of Ultragenyx Pharmaceutical worth $5.58M as of Q2 2026.
  • UBS AM sold 55,822 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.39M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1551 holding.
  • UBS AM first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and has held it in 47 quarters since.
  • UBS AM's Ultragenyx Pharmaceutical position peaked at $10.9M in Q2 2025.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.